Neuropeptide W has cell phenotype-specific effects on the excitability of different subpopulations of paraventricular nucleus neurones.
The administration of the neuropeptide W (NPW) and neuropeptide B (NPB) in rodents has been shown to influence the activity of a variety of autonomic and neuroendocrine systems. The paraventricular nucleus (PVN) is a major autonomic and neuroendocrine integration site in the hypothalamus, and neurones within this nucleus express the receptor for these ligands, NPB/W receptor 1 (NPBWR1). In the present study, we used whole cell patch clamp recordings coupled with single-cell reverse transcriptase-polymerase chain reaction to examine the effects of neuropeptide W-23 (NPW-23) on the excitability of identified PVN neurones. Oxytocin, vasopressin and thyrotrophin-releasing hormone neurones were all found to be responsive to 10 nm NPW-23, although both depolarising and hyperpolarising effects were observed in each of these cell groups. By contrast, corticotrophin-releasing hormone cells were unaffected. Further subdivision of chemically phenotyped cell groups into magnocellular, neuroendocrine or pre-autonomic neurones, using their electrophysiological fingerprints, revealed that neurones projecting to medullary and spinal targets were predominantly inhibited by NPW-23, whereas those that projected to median eminence or neural lobe showed almost equivalent numbers of depolarising and hyperpolarising cells. The demonstration of particular phenotypic populations of PVN neurones showing NPW-induced effects on excitability reinforces the importance of the NPB/NPW neuropeptide system as a regulator of autonomic function.
Price
C J
CJ
Department of Physiology, Queen's University, Kingston, Ontario, Canada.
Samson
W K
WK
Ferguson
A V
AV
D000200:Action Potentials; D000818:Animals; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D008297:Male; D008473:Median Eminence / Q000502:physiology; D008526:Medulla Oblongata / Q000502:physiology; D008564:Membrane Potentials / Q000502:physiology; D009433:Neural Inhibition / Q000502:physiology; D009434:Neural Pathways / Q000502:physiology; D009474:Neurons / Q000502:physiology*; D009479:Neuropeptides / Q000378:metabolism*; D010121:Oxytocin / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000502:physiology; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism; D014667:Vasopressins / Q000378:metabolism
D009479:Neuropeptides; D012333:RNA, Messenger; C496874:neuropeptide W, rat; D014667:Vasopressins; D010121:Oxytocin; D013973:Thyrotropin-Releasing Hormone; D003346:Corticotropin-Releasing Hormone
Brain Res. 2004 Aug 13;1017(1-2):222-6
15261118
Neuroendocrinology. 2008;88(2):88-94
18285680
J Physiol. 2000 Feb 15;523 Pt 1:193-209
10673555
J Endocrinol. 2006 Aug;190(2):213-23
16899556
Physiol Rev. 2000 Oct;80(4):1523-631
11015620
Neurosci Lett. 2007 Jan 3;411(1):67-71
17067739
Nature. 2000 Apr 6;404(6778):661-71
10766253
Endocrinology. 1999 Oct;140(10):4677-82
10499525
J Neuroendocrinol. 2002 Dec;14(12):929-32
12472873
Trends Neurosci. 1999 Feb;22(2):62-7
10092045
J Comp Neurol. 1980 Dec 1;194(3):555-70
7451682
Br J Pharmacol. 2006 Aug;148(8):1033-41
16847439
J Physiol. 2007 Dec 15;585(Pt 3):805-16
17947308
Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R87-96
15044184
Endocrinology. 2009 Feb;150(2):832-40
18948398
J Neuroendocrinol. 2004 Oct;16(10):842-9
15500544
Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1727-32
15886360
Regul Pept. 2007 Feb 1;138(2-3):82-6
17011641
Thyroid. 1998 Oct;8(10):887-94
9827655
Endocrinology. 2003 Jul;144(7):2816-21
12810535
J Biol Chem. 2002 Sep 27;277(39):35826-32
12130646
J Comp Neurol. 2006 Jul 20;497(3):367-83
16736466
Results Probl Cell Differ. 2008;46:239-56
18204824
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6251-6
12719537
Endocrinology. 2003 Nov;144(11):4729-33
12959997
Am J Physiol Regul Integr Comp Physiol. 2005 Jan;288(1):R270-5
15345475